Perceive Biotherapeutics completes VOY-101 Phase 2a JOURNEY enrollment in geographic atrophy
Perceive Bio completes 94-eye VOY-101 enrollment for geographic atrophy. Examine trial design, safety, competition and the 2027 readout.
Pharma & Biotech
Medical Devices & Diagnostics
i-Lumen Scientific begins U.S. pivotal trial of microcurrent therapy for dry AMD
i-Lumen Scientific, Inc. has randomized the first United States patient in its pivotal i-SIGHT2 study, beginning the domestic phase of a multinational trial evaluating whether low-level electrical stimulation delivered through a closed eyelid can improve visual function in people with intermediate-to-advanced dry age-related macular degeneration. The first U.S. randomization occurred at Texas Retina Associates in
Pharma & Biotech
Why Sobi’s EMPAVELI approval in Canada may change the rare kidney disease treatment landscape
Health Canada clears EMPAVELI for C3G and IC-MPGN. Read what this changes for nephrology treatment, market access, and rare kidney disease care.